Lantern Pharma Inc.
LTRN
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers wā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.63
Price-0.76%
-$0.02
1Y
Price
Market Cap
$33.557m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$15.912m
+9.0%
1y CAGR-11.1%
3y CAGR-12.1%
5y CAGREPS
-$1.45
+99.9%
1y CAGR-43722.5%
3y CAGR-32795.8%
5y CAGRBook Value
$3.446m
$7.223m
Assets$3.777m
Liabilities$59.080k
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$15.075m
+5.4%
1y CAGR-10.3%
3y CAGR-12.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company